Tag Archives: Knight Therapeutics

Basilea’s Antifungal Cresemba Sales in Latin America Trigger Milestone Payment from Partner Knight Therapeutics

(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) has announced that its partner Knight Therapeutics Inc. (TSX: GUD) exceeded the sales threshold for the antifungal Cresemba (isavuconazole) in Latin America in 2023, triggering the first sales milestone payment for the region. … Read the full press release